These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 31901950)

  • 1. Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study (IDMPS).
    Aschner P; Gagliardino JJ; Ilkova H; Lavalle F; Ramachandran A; Mbanya JC; Shestakova M; Chantelot JM; Chan JCN
    Diabetologia; 2020 Apr; 63(4):711-721. PubMed ID: 31901950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Rate of Insulin use and Suboptimal Glycemic Control among Egyptian Patients with T2DM: Cohort Analysis of Eighth Wave of the International Diabetes Management Practices Study (IDMPS).
    Khalil SHA; Khaled M; Zakhary R; Shereen M
    Curr Diabetes Rev; 2024; 20(3):e020623217590. PubMed ID: 37264625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management and control of patients with type 2 diabetes mellitus in Lebanon: results from the International Diabetes Management Practices Study (IDMPS).
    Azar ST; Malha LP; Zantout MS; Naja M; Younes F; Sawaya MT
    J Med Liban; 2013; 61(3):127-31. PubMed ID: 24422361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct trajectories of HbA
    Rathmann W; Schwandt A; Hermann JM; Kuss O; Roden M; Laubner K; Best F; Ebner S; Plaumann M; Holl RW;
    Diabet Med; 2019 Nov; 36(11):1468-1477. PubMed ID: 31392761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of a fasting-mimicking diet programme in primary care for type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month randomised controlled trial.
    van den Burg EL; Schoonakker MP; van Peet PG; van den Akker-van Marle EM; Lamb HJ; Longo VD; Numans ME; Pijl H
    Diabetologia; 2024 Jul; 67(7):1245-1259. PubMed ID: 38546821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
    Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One in Seven Insulin-Treated Patients in Developing Countries Reported Poor Persistence with Insulin Therapy: Real World Evidence from the Cross-Sectional International Diabetes Management Practices Study (IDMPS).
    Chan JCN; Gagliardino JJ; Ilkova H; Lavalle F; Ramachandran A; Mbanya JC; Shestakova M; Dessapt-Baradez C; Chantelot JM; Aschner P
    Adv Ther; 2021 Jun; 38(6):3281-3298. PubMed ID: 33978906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.
    Owens DR; Landgraf W; Frier BM; Zhang M; Home PD; Meneghini L; Bolli GB
    Diabetes Obes Metab; 2019 Feb; 21(2):321-329. PubMed ID: 30520217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial.
    Punthakee Z; Miller ME; Simmons DL; Riddle MC; Ismail-Beigi F; Brillon DJ; Bergenstal RM; Savage PJ; Hramiak I; Largay JF; Sood A; Gerstein HC;
    Diabetologia; 2014 Oct; 57(10):2030-7. PubMed ID: 24985147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of blinded retrospective continuous glucose monitoring on clinical decision making and glycemic control in persons with type 2 diabetes on insulin therapy.
    Ribeiro RT; Andrade R; Nascimento do Ó D; Lopes AF; Raposo JF
    Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1267-1275. PubMed ID: 33612381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, usability and sequence of operations of a workflow-integrated algorithm for basal-bolus insulin therapy in hospitalized type 2 diabetes patients.
    Mader JK; Neubauer KM; Schaupp L; Augustin T; Beck P; Spat S; Höll B; Treiber GM; Fruhwald FM; Pieber TR; Plank J
    Diabetes Obes Metab; 2014 Feb; 16(2):137-46. PubMed ID: 23910952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study.
    Balkau B; Calvi-Gries F; Freemantle N; Vincent M; Pilorget V; Home PD
    Diabetes Res Clin Pract; 2015 Jun; 108(3):432-40. PubMed ID: 25818885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).
    Rodbard HW; Tripathy D; Vidrio Velázquez M; Demissie M; Tamer SC; Piletič M
    Diabetes Obes Metab; 2017 Oct; 19(10):1389-1396. PubMed ID: 28345792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
    Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
    Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting.
    Meneghini LF; Mauricio D; Orsi E; Lalic NM; Cali AMG; Westerbacka J; Stella P; Candelas Dea C; Pilorget V; Perfetti R; Khunti K;
    Diabetes Obes Metab; 2019 Jun; 21(6):1429-1436. PubMed ID: 30768845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.
    Meneghini L; Doshi A; Gouet D; Vilsbøll T; Begtrup K; Őrsy P; Ranthe MF; Lingvay I
    Diabet Med; 2020 Feb; 37(2):267-276. PubMed ID: 31705547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets.
    Dalal MR; Grabner M; Bonine N; Stephenson JJ; DiGenio A; Bieszk N
    Diabetes Res Clin Pract; 2016 Nov; 121():17-26. PubMed ID: 27616634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare Type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study.
    Manski-Nankervis J; Yates CJ; Blackberry I; Furler J; Ginnivan L; Cohen N; Jenkins A; Vasanthakumar S; Gorelik A; Young D; Best J; O'Neal D
    Diabet Med; 2016 Jun; 33(6):803-11. PubMed ID: 26435033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.